Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed that it bought back 53,000 H-shares on 4 September 2026 via on-market transactions in Hong Kong.

The repurchases were executed at prices ranging from HKD 21.68 to HKD 22.00 per share, for a total cash outlay of HKD 1.16 million (approximately RMB 1.12 million). The volume-weighted average repurchase price reported in Section I was RMB 21.89 per share.

Key impacts on share capital: • Issued shares (excluding treasury stock) decreased to 323.20 million from 323.25 million, a marginal reduction of 0.016%. • Treasury shares increased to 13.15 million, while the company’s total issued share count remained unchanged at 336.35 million.

Repurchase mandate utilisation: • The general mandate approved on 13 May 2026 authorises Zylox-Tonbridge to buy back up to 32.72 million shares. • Cumulative repurchases under this mandate now total 4.25 million shares, equating to 1.27% of the outstanding shares at the mandate date and leaving capacity for a further 28.46 million shares. • In line with Hong Kong listing rules, the company is subject to a 30-day moratorium—until 4 October 2026—on issuing, selling or transferring shares following the latest buyback.

All repurchases were executed in compliance with the Hong Kong Stock Exchange’s Main Board Rules, and the repurchased shares will be held as treasury stock pending any future corporate actions.